## Vicent BalanzÃ;-MartÃ-nez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1327857/publications.pdf

Version: 2024-02-01

134 papers 6,699 citations

41 h-index

71102

69250 77 g-index

141 all docs

141 docs citations

141 times ranked

7262 citing authors

#	Article	IF	CITATIONS
1	Longâ€term neuropsychiatric outcomes in COVIDâ€19 survivors: A 1â€year longitudinal study. Journal of Internal Medicine, 2022, 291, 247-251.	6.0	44
2	Lifestyle predictors of depression and anxiety during COVID-19: a machine learning approach. Trends in Psychiatry and Psychotherapy, 2022, , .	0.8	2
3	Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study. Journal of Affective Disorders, 2022, 300, 99-108.	4.1	3
4	Gender Differences in Psychological Stress Factors of Physical Therapy Degree Students in the COVID-19 Pandemic: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 810.	2.6	20
5	Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disorders, 2022, 24, 354-374.	1.9	23
6	Psiquiatria do Estilo de Vida:Um Horizonte Promissor para os Cuidados de Saúde Mental. , 2022, 8, 2-3.	0.1	0
7	Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders. Acta Psychiatrica Scandinavica, 2022, 146, 215-226.	4.5	7
8	Lifestyle Prescription for Depression with a Focus on Nature Exposure and Screen Time: A Narrative Review. International Journal of Environmental Research and Public Health, 2022, 19, 5094.	2.6	2
9	The network structure of cognitive deficits in first episode psychosis patients. Schizophrenia Research, 2022, 244, 46-54.	2.0	2
10	Immune–Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study. Frontiers in Neurology, 2022, 13, .	2.4	4
11	The effect of concomitant benzodiazepine use on neurocognition in stable, long-term patients with bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2021, 55, 1005-1016.	2.3	10
12	The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 16-26.	1.8	118
13	Cumulative Cardiovascular Disease Risk and Triglycerides Differentially Relate to Subdomains of Executive Function in Bipolar Disorder; preliminary findings. Journal of Affective Disorders, 2021, 278, 556-562.	4.1	10
14	Expert consensus on information sheet proposals for patients under treatment with lithium. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 27-39.	0.3	0
15	The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 16-26.	0.3	5
16	Consenso de expertos sobre propuestas de información al paciente en tratamiento con sales de litio. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 27-39.	1.8	6
17	â€~An Apple a Day'?: Psychiatrists, Psychologists and Psychotherapists Report Poor Literacy for Nutritional Medicine: International Survey Spanning 52 Countries. Nutrients, 2021, 13, 822.	4.1	18
18	Shortâ€term neuropsychiatric outcomes and quality of life in COVIDâ€19 survivors. Journal of Internal Medicine, 2021, 290, 621-631.	6.0	146

#	Article	IF	CITATIONS
19	Cognitive impairment and consumption of mental healthcare resources in outpatients with bipolar disorder. Journal of Psychiatric Research, 2021, 138, 535-540.	3.1	2
20	Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. International Journal of Environmental Research and Public Health, 2021, 18, 8133.	2.6	7
21	A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis. International Journal of Environmental Research and Public Health, 2021, 18, 7239.	2.6	7
22	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.9	27
23	The cumulative effect of multiple dimensions of lifestyle on risky drinking during the Covid-19 pandemic. Preventive Medicine, 2021, 150, 106718.	3.4	8
24	Is processing speed a valid neurocognitive endophenotype in bipolar disorder? Evidence from a longitudinal, family study. Journal of Psychiatric Research, 2021, 141, 241-247.	3.1	10
25	La humanización en los planes de salud mental en España. Revista De PsiquiatrÃa Y Salud Mental, 2021, , .	1.8	2
26	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. Schizophrenia Research, 2021, 236, 19-28.	2.0	5
27	Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. Journal of Affective Disorders, 2021, 295, 173-182.	4.1	32
28	Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking. European Psychiatry, 2021, 64, e22.	0.2	8
29	Spanish validation of the Empirically Developed Clinical Staging Model (EmDe-5) for patients with bipolar disorder. Revista De PsiquiatrÃa Y Salud Mental, 2021, , .	1.8	O
30	Dejar de fumar en el trastorno mental grave: desafÃos y oportunidades en tiempos de la COVID-1. Revista De Psicologia De La Salud, 2021, 33, 175.	0.5	1
31	What Are We Measuring When We Evaluate Digital Interventions for Improving Lifestyle? A Scoping Meta-Review. Frontiers in Public Health, 2021, 9, 735624.	2.7	6
32	Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: An overview of evidence. Bipolar Disorders, 2020, 22, 13-27.	1.9	89
33	Grip Strength, Neurocognition, and Social Functioning in People WithType-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia. Frontiers in Psychology, 2020, 11, 525231.	2.1	9
34	Lifestyle behaviours during the COVIDâ€19 – time to connect. Acta Psychiatrica Scandinavica, 2020, 141, 399-400.	4.5	183
35	Lifetime cocaine use is a potential predictor for conversion from major depressive disorder to bipolar disorder: A prospective study. Psychiatry and Clinical Neurosciences, 2020, 74, 418-423.	1.8	9
36	Virtual meetings and social isolation in COVID-19 times: transposable barriers. Trends in Psychiatry and Psychotherapy, 2020, 42, 221-222.	0.8	7

#	Article	IF	CITATIONS
37	Diet and Neurocognition in Mood Disorders - An Overview of the Overlooked. Current Pharmaceutical Design, 2020, 26, 2353-2362.	1.9	11
38	Peripheral Oxidative Stress Markers in Patients with Bipolar Disorder during Euthymia and in Siblings. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 77-86.	1.2	9
39	Depression, Anxiety, and Lifestyle Among Essential Workers: A Web Survey From Brazil and Spain During the COVID-19 Pandemic. Journal of Medical Internet Research, 2020, 22, e22835.	4.3	56
40	Development and implementation of guidelines for the management of depression: a systematic review. Bulletin of the World Health Organization, 2020, 98, 683-697H.	3.3	25
41	Prevalence of depressive symptoms and suicidal ideation among Spanish medical students. Actas Espanolas De Psiquiatria, 2020, 48, 154-62.	0.1	7
42	Visual memory dysfunction as a neurocognitive endophenotype in bipolar disorder patients and their unaffected relatives. Evidence from a 5-year follow-up Valencia study Journal of Affective Disorders, 2019, 257, 31-37.	4.1	12
43	"Readiness to Change―Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. European Addiction Research, 2019, 25, 256-262.	2.4	3
44	Neurocognitive endophenotypes in schizophrenia and bipolar disorder: A systematic review of longitudinal family studies. Schizophrenia Research, 2019, 210, 21-29.	2.0	23
45	Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate) Tj ETQq1	1.678431	4 <sub>4</sub> rgBT /Ove
46	Subjective neurocognition and quality of life in patients with bipolar disorder and siblings. Journal of Affective Disorders, 2019, 245, 283-288.	4.1	21
47	Preparando el escenario para dejar de fumar en el paciente con Trastorno Bipolar: intervención breve en la práctica clÃnica. Revista De Psicologia De La Salud, 2019, 31, 136.	0.5	7
48	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. Psychological Medicine, 2018, 48, 2247-2256.	4.5	40
49	Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables. Acta Psychiatrica Scandinavica, 2018, 138, 145-154.	4.5	60
50	Tobacco smoking and its association with cognition in first episode psychosis patients. Schizophrenia Research, 2018, 192, 269-273.	2.0	34
51	Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 699-711.	3.2	31
52	Staging, Neurocognition and Social Functioning in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 709.	2.6	21
53	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neuroscience and Biobehavioral Reviews, 2018, 94, 11-16.	6.1	102
54	Duration of euthymia and predominant polarity in bipolar disorder. Journal of Affective Disorders, 2018, 241, 356-359.	4.1	12

#	Article	IF	Citations
55	Cognitive reserve as an outcome predictor: firstâ€episode affective versus nonâ€affective psychosis. Acta Psychiatrica Scandinavica, 2018, 138, 441-455.	4.5	66
56	A preliminary study to assess the impact of maternal age on stress-related variables in healthy nulliparous women. Psychoneuroendocrinology, 2017, 78, 97-104.	2.7	29
57	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. European Neuropsychopharmacology, 2017, 27, 350-359.	0.7	26
58	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophrenia Research, 2017, 189, 84-90.	2.0	49
59	Clinical staging and serum cytokines in bipolar patients during euthymia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 194-201.	4.8	37
60	Manual motor speed dysfunction as a neurocognitive endophenotype in euthymic bipolar disorder patients and their healthy relatives. Evidence from a 5-year follow-up study. Journal of Affective Disorders, 2017, 215, 156-162.	4.1	26
61	High Cognitive Reserve in Bipolar Disorders as a Moderator of Neurocognitive Impairment. European Psychiatry, 2017, 41, S116-S116.	0.2	О
62	High cognitive reserve in bipolar disorders as a moderator of neurocognitive impairment. Journal of Affective Disorders, 2017, 208, 621-627.	4.1	51
63	Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment. Frontiers in Psychiatry, 2017, 8, 173.	2.6	42
64	Persistent Negative Symptoms in First-Episode Psychosis. Journal of Clinical Psychiatry, 2017, 78, 1414-1422.	2.2	28
65	The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia. Current Pharmaceutical Design, 2016, 22, 6122-6133.	1.9	39
66	Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. Acta Psychiatrica Scandinavica, 2016, 133, 386-398.	4.5	103
67	Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. Psychological Medicine, 2016, 46, 291-301.	4.5	43
68	Quality of Life, Cognition, and Social Cognition in Schizophrenia., 2016,, 25-51.		2
69	The possible resilience role of cognitive reserve in bipolar disorder. European Neuropsychopharmacology, 2016, 26, S428-S429.	0.7	1
70	Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD. Journal of Attention Disorders, 2016, 20, 1066-1075.	2.6	88
71	Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: A systematic review. Journal of Psychiatric Research, 2016, 74, 1-7.	3.1	87
72	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. International Journal of Neuropsychopharmacology, 2016, 19, pyv121.	2.1	29

#	Article	IF	CITATIONS
<b>7</b> 3	Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. British Journal of Psychiatry, 2016, 208, 87-93.	2.8	95
74	Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas, 2016, 83, 83-93.	2.4	39
<b>7</b> 5	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. PLoS ONE, 2016, 11, e0160949.	2.5	22
76	<scp>I</scp> nternational <scp>S</scp> ociety for <scp>N</scp> utritional <scp>P</scp> sychiatry <scp>R</scp> esearch consensus position statement: nutritional medicine in modern psychiatry. World Psychiatry, 2015, 14, 370-371.	10.4	81
77	Attention-deficit hyperactivity disorder (ADHD), substance use disorders, and criminality: a difficult problem with complex solutions. International Journal of Adolescent Medicine and Health, 2015, 27, 163-175.	1.3	41
78	Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). Experimental and Therapeutic Medicine, 2015, 9, 643-652.	1.8	26
79	Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry,the, 2015, 2, 271-274.	7.4	375
80	Predictors of functional outcome after a manic episode. Journal of Affective Disorders, 2015, 182, 121-125.	4.1	16
81	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophrenia Research, 2015, 164, 65-73.	2.0	92
82	Natural environments, ancestral diets, and microbial ecology: is there a modern "paleo-deficit disorder� Part II. Journal of Physiological Anthropology, 2015, 34, 9.	2.6	25
83	Natural environments, ancestral diets, and microbial ecology: is there a modern "paleo-deficit disorder� Part I. Journal of Physiological Anthropology, 2015, 34, 1.	2.6	43
84	Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. Frontiers in Physiology, 2015, 6, 108.	2.8	35
85	Functional remediation for patients with bipolar II disorder: Improvement of functioning and subsyndromal symptoms. European Neuropsychopharmacology, 2015, 25, 257-264.	0.7	52
86	The prevalence of bipolar disorders in the general population: a growing trending topic?. Revista Brasileira De Psiquiatria, 2015, 37, 91-92.	1.7	0
87	Staging and early intervention in bipolar disorder. , 2015, , 269-282.		O
88	The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology, 2014, 4, 198-219.	2.7	224
89	Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies. Psychotherapy and Psychosomatics, 2014, 83, 89-105.	8.8	164
90	Integrated treatment of first episode psychosis with online training (e-learning): study protocol for a randomised controlled trial. Trials, 2014, 15, 416.	1.6	12

#	Article	IF	CITATIONS
91	Staging systems in bipolar disorder: an <scp>I</scp> nternational <scp>S</scp> ociety for <scp>B</scp> ipolar <scp>D</scp> isorders <scp>T</scp> ask <scp>F</scp> orce <scp>R</scp> eport. Acta Psychiatrica Scandinavica, 2014, 130, 354-363.	4.5	175
92	Differential associations of cognitive insight components with pretreatment characteristics in first-episode psychosis. Psychiatry Research, 2014, 215, 308-313.	3.3	13
93	Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. Journal of Affective Disorders, 2014, 160, 50-54.	4.1	71
94	Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data metaâ€analysis. Acta Psychiatrica Scandinavica, 2013, 128, 149-162.	4.5	481
95	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. European Psychiatry, 2013, 28, 21-29.	0.2	119
96	Efficacy of Functional Remediation in Bipolar Disorder: A Multicenter Randomized Controlled Study. American Journal of Psychiatry, 2013, 170, 852-859.	7.2	269
97	Understanding Bipolar Disorder in Late Life. Journal of Nervous and Mental Disease, 2013, 201, 674-679.	1.0	16
98	Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). International Journal of Neuropsychopharmacology, 2013, 16, 513-523.	2.1	33
99	Attention Deficit Hyperactivity Disorder (ADHD) in the adult patients: view of the clinician. Actas Espanolas De Psiquiatria, 2013, 41, 185-95.	0.1	3
100	Neurocognitive Training in Patients with Bipolar Disorders: Current Status and Perspectives. Psychotherapy and Psychosomatics, 2012, 81, 250-252.	8.8	26
101	Development of the insight scale for affective disorders (ISAD): Modification from the scale to assess unawareness of mental disorder. Journal of Affective Disorders, 2012, 142, 65-71.	4.1	30
102	Clinical factors leading to lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study. Journal of Affective Disorders, 2012, 143, 102-108.	4.1	14
103	Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatrica Scandinavica, 2012, 126, 315-331.	4.5	111
104	Neurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatrica Scandinavica, 2012, 125, 309-317.	4.5	78
105	Symptomatic remission in schizophrenia patients: Relationship with social functioning, quality of life, and neurocognitive performance. Schizophrenia Research, 2011, 129, 133-136.	2.0	96
106	Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Review of Neurotherapeutics, 2011, 11, 1029-1047.	2.8	87
107	Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Comprehensive Psychiatry, 2011, 52, 613-622.	3.1	91
108	The impact of a history of psychotic symptoms on cognitive function in euthymic bipolar patients: a comparison with schizophrenic patients and healthy controls. Revista Brasileira De Psiquiatria, 2011, 33, 353-361.	1.7	29

#	Article	IF	CITATIONS
109	Suitable cognitive endophenotypes from a family and prospective study of schizophrenia and bipolar disorder. International Clinical Psychopharmacology, 2011, 26, e62-e63.	1.7	O
110	Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community?. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 509-517.	3.2	31
111	Should bipolar disorder be considered a systemic illness?. Neuropsychiatry, 2011, 1, 45-54.	0.4	3
112	Neurocognition in bipolar disorders—A closer look at comorbidities and medications. European Journal of Pharmacology, 2010, 626, 87-96.	3.5	105
113	Functional impairment in bipolar II disorder: Is it as disabling as bipolar I?. Journal of Affective Disorders, 2010, 127, 71-76.	4.1	75
114	The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. BMC Psychiatry, 2010, 10, 47.	2.6	13
115	Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Annals of General Psychiatry, 2010, 9, .	2.7	1
116	Detection of Subclinical Depression in Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, 1465-1474.	2.2	18
117	Longitudinal course of cognition in schizophrenia. British Journal of Psychiatry, 2009, 195, 84-84.	2.8	2
118	Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients. Psychiatry Research, 2009, 169, 220-228.	3.3	90
119	Rendimiento psicométrico del Cuestionario Oviedo de Sueño en pacientes con trastorno mental grave. Revista De PsiquiatrÃa Y Salud Mental, 2009, 2, 169-177.	1.8	21
120	Motor speed predicts stability of cognitive deficits in both schizophrenic and bipolar I patients at one-year follow-up. European Journal of Psychiatry, 2009, 23, .	1.3	9
121	Neurocognitive endophenotypes (Endophenocognitypes) from studies of relatives of bipolar disorder subjects: A systematic review. Neuroscience and Biobehavioral Reviews, 2008, 32, 1426-1438.	6.1	189
122	Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. Journal of Affective Disorders, 2008, 109, 286-299.	4.1	256
123	Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. Psychiatric Genetics, 2008, 18, 313-317.	1.1	22
124	Neurocognitive Impairment in Bipolar Patients With and Without History of Psychosis. Journal of Clinical Psychiatry, 2008, 69, 233-239.	2.2	142
125	Bipolar I patients with and without a history of psychotic symptoms: Do they differ in their cognitive functioning?. Journal of Psychiatric Research, 2007, 41, 265-272.	3.1	89
126	Specificity of Cognitive Deficits in Bipolar Disorder versus Schizophrenia. Psychotherapy and Psychosomatics, 2006, 75, 72-84.	8.8	185

#	Article	IF	CITATIONS
127	Variations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from mediterranean Spain: A preliminary study. Neuroscience, 2006, 139, 1289-1300.	2.3	47
128	Persistent Cognitive Dysfunctions in Bipolar I Disorder and Schizophrenic Patients: A 3-Year Follow-Up Study. Psychotherapy and Psychosomatics, 2005, 74, 113-119.	8.8	143
129	Recall and recognition confabulation in psychotic and bipolar disorders: evidence for two different types without unitary mechanisms. Comprehensive Psychiatry, 2004, 45, 281-288.	3.1	33
130	Specific executive/attentional deficits in patients with schizophrenia or bipolar disorder who have a positive family history of psychosis. Journal of Psychiatric Research, 2003, 37, 479-486.	3.1	47
131	Abnormal motor asymmetry only during bimanual movement in schizophrenic patients compared with healthy subjects. Schizophrenia Research, 2003, 61, 245-253.	2.0	13
132	Similar effect of family history of psychosis on Sylvian fissure size and auditory P200 amplitude in schizophrenic and bipolar subjects. Psychiatry Research - Neuroimaging, 2001, 108, 29-38.	1.8	16
133	Neuroplasticidad y deterioro cognitivo en trastornos mentales graves desde un enfoque neuropsicol $\tilde{A}^3$ gico. , 0, , .		O
134	Lifestyle Behaviors, Depression, and Anxiety Among Individuals Living in Canada During the COVID-19 Pandemic. American Journal of Lifestyle Medicine, 0, , 155982762211020.	1.9	0